HALL A
|
|
|
Screening and treating thrombophilia |
Chairpersons |
Jean Christophe Gris, France Aharon Lubetsky, Israel |
08:30-09:20 08:30 08:50 09:10
|
Debate: Role of low molecular weight heparin in pregnancy complications:
Major: Jean-Christophe Gris, France Minor: Benjamin Brenner, Israel
Discussion
|
09:20-09:40 |
State of the Art: What is the role of thrombophilia in venous thromboembolism? Aharon Lubetsky, Israel
|
09:40-09:50 |
The dominant antithrombin Budapest 3 mutation in the Hungarian population is caused by a founder effect; genotype-phenotype relations investigated in a large cohort Zsuzsanna Bereczky, Hungary
|
09:50-10:00 |
Inherited thrombophilia in women with unexplained recurrent pregnancy loss or idiopathic infertility: Reproductive friend or foe? Valeria Raparelli, Italy
|
HALL A
|
|
10:30-11:40 |
Pharmacogenomics and thrombolytic therapy
|
Chairpersons |
Yosef Caraco, Israel Emilio Clementi, Italy |
10:30-10:50
|
State of the Art: Catheter guided thrombolysis for deep vein thrombosis and pulmonary embolism Alan Bloom, Israel
|
10:50-11:40 10:50 11:10 11:30 |
Debate: Pharmacogenomics in antithrombotic therapy
Advantages: Yosef Caraco, Israel Limitations: Emilio Clementi, Italy
Discussion
|
HALL A |
|
16:30-17:40
|
Antiplatelet treatment and its monitoring
|
Chairpersons |
Marco Cattaneo, Italy Giovanni Davì, Italy
|
16:30-17:20 16:30 16:50 17:10
|
Debate: New antiplatelet agents Advantages: Giovanni Davì, Italy Limitations: Marco Cattaneo, Italy Discussion |
17:20-17:40
|
State of the Art: Monitoring antiplatelet therapy Marco Cattaneo, Italy
|
HALL A
|
|
17:40-18:00
|
Immune thrombocytopenic purpura
|
Chairperson: |
David Varon, Israel
|
|
State of the Art: Thrombopoietins for immune thrombocytopenic purpura and beyond James Bussel, USA
|
Saturday, November 7, 2015
HALL A |
|
|
New oral anticoagulants for the treatment of venous thromboembolism and atrial fibrillation
|
Chairpersons |
Giancarlo Agnelli, Italy Benjamin Brenner, Israel
|
08:30-09:20
08:30
08:50 09:10
|
Debate: New oral anticoagulants for treatment and prevention of venous thromboembolism Advantages: Giancarlo Agnelli, Italy
Limitations: Aharon Lubetsky, Israel Discussion
|
09:20-10:10
09:20 09:40 10:00
|
Debate: New oral anticoagulants in cardiology
Advantages: Giovanni Davì, Italy
Limitations: Benjamin Brenner, Israel Discussion
|
10:10-10:20
|
“Real word” initial experience on safety and efficacy with Ticagrelor vs. Clopidogrel in acute coronary syndromes Michel Butron-Calderon, Spain |
10:20-10:30 |
A risk score for prediction of recurrence in patients with unprovoked venousthromboembolism (DAMOVES) Ana Isabel Franco, Spain
|
HALL A |
|
|
Antithrombotics for patient subgroups
|
Chairpersons |
Eduardo Arellano-Rodrigo, Spain Pier M. Mannucci, Italy
|
14:00-14:50 14:00 14:20
14:40
|
Debate: Anti thrombotics for atrial fibrillation (AF) in the oldest old
Vitamin K antagonists: Pier M. Mannucci, Italy
Direct oral anticoagulants: Paolo Prandoni, Italy Discussion
|
14:50-15:40 14:50 15:10 15:30
|
Debate: Secondary prophylaxis of thrombosis in myeloproliferative neoplasms
Yes: Eduardo Arellano-Rodrigo, Spain
No: Gunnar Birgegard, Sweden Discussion
|
HALL A |
|
|
Prevention of venous thromboembolism and coronary artery disease
|
Chairpersons |
Sergio Coccheri, Italy Carlo Patrono, Italy
|
16:10-17:00 16:10 16:30 16:50
|
Debate: Extended venous thromboembolism prophylaxis
Advantages: Paolo Prandoni, Italy
Limitations: Giancarlo Agnelli, Italy Discussion
|
17:00-17:50 17:00 17:20 17:40 |
Debate: Primary prevention with aspirin of coronary and cerobrovascular artery disease
Advantages: Carlo Patrono, Italy
Limitations: Sergio Coccheri, Italy Discussion
|